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ABSTRACT
DNA methylation is important for gene expression and genome stability, and its 
disruption is thought to play a key role in the initiation and progression of cancer and 
other diseases. The DLK1-DIO3 cluster has been shown to be imprinted in humans, and 
some of its components are relevant to diverse pathological processes. The purpose of 
this study was to assess the methylation patterns of the DLK1-DIO3 cluster in patients 
with lung cancer to study its relevance in the pathogenesis of this disease. We found 
a characteristic methylation pattern of this cluster in smoking associated lung cancer, 
as compared to normal lung tissue. This methylation profile is not patent however 
in lung cancer of never smokers nor in lung tissue of COPD patients. We found 3 
deregulated protein-coding genes at this locus: one was hypermethylated (DIO3) 
and two were hypomethylated (DLK1 and RTL1). Statistically significant differences 
were also detected in two different families of SNORDs, two miRNA clusters and 
four lncRNAs (MEG3, MEG8, MEG9 and LINC00524). These findings were validated 
using data from the cancer genome atlas (TCGA) database. We have then showed an 
inverse correlation between DNA methylation and expression levels in 5 randomly 
selected genes. Several targets of miRNAs included in the DLK1-DIO3 cluster have 
been experimentally verified as tumor suppressors. All of these results suggest that 
the dysmethylation of the imprinted DLK1-DIO3 cluster could have a relevant role in 
the pathogenesis of lung cancer in current and former smokers and may be used for 
diagnostic and/or therapeutic purposes.
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INTRODUCTION
Lung cancer is a highly incident disease, commonly 
associated to tobacco exposure, and currently represents 
the most frequent cause of cancer mortality. More than 
80% of the cases present non-small cell lung cancer 
(NSCLC) histology, including adenocarcinoma and 
squamous cell carcinoma [1, 2]. Many molecular analyses 
have shown the complexity driving the carcinogenesis of 
the clinically relevant lung cancer phenotypes [3]. This 
includes DNA methylation patterns that undergo complex 
changes in cancer [4]. This process is important for gene 
expression and genome stability, and its disruption is 
thought to play a key role in the initiation and progression 
of lung cancer [5].
According to classical Mendelian laws, the majority 
of genes in a human cell are inherited in two functionally 
equivalent parental copies. However, there is a small 
subset of genes with one turned-off copy in a parent-of-
origin-dependent manner[6]. This phenomenon, known as 
genomic imprinting, is an epigenetic process that involves 
monoallelic expression. Some genes are imprinted across 
the complete genome sequence, but the vast majority of 
imprinted genes are clustered [7, 8]. Genomic imprinting 
occurs in many diseases, such as neurological disorders, 
cancer and many others [9-11]. Loss of imprinting is 
commonly observed in human tumors [12], suggesting the 
presence of the imbalanced expression of imprinted tumor-
suppressor genes or oncogenes. The IGF2 and P73 genes 
have been pointed out as examples of imprinted oncogene 
and tumor suppressor gene, respectively, in several tumors 
[11, 13-20].
The DLK1-DIO3 imprinted cluster is located 
on chromosome 14q32.2. This region includes 
protein-coding genes (DLK1, RTL1 and DIO3), 
long non-coding RNAs (MEG3, MEG8, MEG9 and 
LINC00524), two large clusters of miRNAs, two families 
of small nucleolar RNAs (SNORD113 and SNORD114) 
and several pseudogenes [21]. Aberrations involving 
some components of the DLK1-DIO3 cluster have been 
linked to pathological processes [22]. Increased DLK1 
levels may become oncogenic in NSCLC by upregulating 
cell cycle machinery, which has been proposed 
to be highly associated with tumor invasion [23]. 
Similarly, overexpression of the RTL1 gene promotes 
hepatocarcinogenesis [24]. miRNAs located in the 
DLK1-DIO3 cluster have been shown to be involved in 
the development of different tumors such as lymphomas, 
glioblastomas, gastric tumors, and many others [22]. At 
the same time, it has been demonstrated that SNORD113 
expression is linked to decreased survival in patients with 
hepatocellular carcinoma [25]. Concerning lung cancer, 
Valdmanis et al. recently described that the expression of 
a cluster of ~53 microRNAs and mRNAs at the DLK1-
DIO3 locus on mouse chromosome 12qF1 was markedly 
increased in tumors compared to non-tumoral tissue, and 
they have proposed a role for the cluster in the origin 
of cancer cells [26]. Altogether, the aforementioned 
data suggest aberrant epigenetic regulation in genomic 
imprinting may promote imbalanced growth, thus 
leading to human tumorigenesis. To elucidate the role 
of the DLK1-DIO3 cluster in the tumorigenesis of non-
small cell lung cancer, we have analyzed the methylation 
pattern in lung tumors as compared to non-tumoral lung 
tissue.
RESULTS
DNA methylation pattern of the DLK1-DIO3 
cluster in lung cancer
To evaluate the potential role of the DLK1-DIO3 
cluster in lung cancer, we analyzed the methylation status 
of the cluster in human lung tissue. The methylation 
profile of DLK1-DIO3 was evaluated in human tumor 
samples and compared to non-tumoral tissue using the 
Illumina Infinium Human Methylation 450 BeadChip. The 
methylation levels in lung cancer versus non-tumoral tissue 
are represented in Figure 1A and Supplementary Table 
S1. Patients with lung cancer showed three deregulated 
protein-coding genes: one was hypermethylated (DIO3) 
and two were hypomethylated (DLK1 and RTL1). 
Statistically significant differences (adjusted p-value 
< 0.05) were also detected in two different families 
of SNORDs (SNORD113 and SNORD114), with the 
exception of SNORD114-30 that showed a similar 
but non-significant pattern of DNA hypomethylation 
(p=0.07), (Table 1). Similarly, two miRNA clusters and 
four lncRNAs (MEG3, MEG8, MEG9 and LINC00524) 
were found to be significantly less methylated in tumors as 
compared to non-tumoral tissue (Figure 1B and Table 1). 
To validate these findings we used methylation data from 
an independent cohort obtained from TCGA database, and 
a different method of analysis. Consistently significant 
differences in methylation were observed again for the 
DLK1-DIO3 cluster (Figure 2). All genes included in 
the cluster show a hypomethylated pattern with the 
exception of DIO3 that was hypermethylated in tumor 
tissue. In order to investigate methylation-dependent 
RNA expression changes, some components of the DLK1-
DIO3 cluster, such as DIO3, SNORD113-5, SNORD113-7, 
SNORD114-9, and miR-889, were randomly selected to 
analyze their expression levels in matched normal-tumor 
samples. The results confirmed that the methylation levels 
were inversely associated with the expression levels, 
i.e., hypomethylation of SNORD113-5, SNORD113-7, 
SNORD114-9, and miR-889 correlated with high gene 
expression in tumor samples relative to non-tumoral 
tissue. In the case of DIO3, we found lower levels of 
mRNA expression in lung tumor tissue (Figure 3).
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DLK1-DIO3 methylation profile by smoking 
characteristics
We evaluated variations of the DLK1-DIO3 
methylation profile of lung tissues, tumoral and non-
tumoral, according to the prior smoking exposure of 
patients. We found no differences on cluster DLK1-DIO3 
methylation between non-tumoral and tumoral lung tissue 
among never smokers (Figure 4A). The methylation status 
of DIO3, miR-889 and SNORD114-9 was further validated 
by 454 bisulfite sequencing using pooled non-tumor and 
tumor samples from non-smokers (Figure 4B). In current 
and former smokers with lung cancer, the DLK1-DIO3 
cluster showed higher methylation in non-tumoral tissue 
as compared to tumor. In the latter group of patients, 
statistically significant differences in methylation were 
identified in all components of the DLK1-DIO3 cluster 
(adjusted p-value< 0.001) (Figure 4C).
We then next analyzed whether the DNA 
methylation pattern in non-tumoral lung parenchyma of 
current and former smokers with COPD differed from that 
of current and former smokers without COPD and found 
no statistical differences (Figure 1B). Of note, an increase 
in the DNA promoter methylation of DIO3 was noticeable 
in COPD lung tissue although not statistically significant 
(log2 ratio COPD
+/COPD-LC- was 0.535 and the adjusted 
p-value was 0.840) (Supplementary Table S1). In addition, 
we have found that the DLK1-DIO3 methylation profile of 
non-malignant tissue from lung cancer patients and control 
subjects was similar (data not shown).
Figure 1: Methylation profile of the DLK1-DIO3 cluster in lung cancer. A. The DLK1-DIO3 cluster is located on chromosome 
14 (14q32). Using a Circos plot, we plotted the methylation levels on chromosome 14. From inside to outside: methylation levels, ideogram 
and gene labels. Hypermethylation (red dots and green background) and hypomethylation events (green dots and red background) in 
patients with lung cancer versus non-tumoral samples. (Continued)
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DLK1-DIO3 methylation profile by histological 
subtypes
Due to its specific global hypomethylation in 
lung cancer, we have evaluated the methylation of 
the DLK1-DIO3 cluster in the two main histological 
subtypes of NSCLC, squamous cell carcinoma 
(SCC) and adenocarcinoma, as compared to non-
tumoral tissue. The DLK1-DIO3 imprinted cluster 
hypomethylation was consistently evident in both 
Figure 1: (Continued) Methylation profile of the DLK1-DIO3 cluster in lung cancer. B. Observed methylation changes 
(log2 ratio). Relative levels of methylation in patients with lung cancer relative to the control group are represented in blue bars, whereas 
methylation levels of COPD patients with respect to the control group are represented by red bars. A grey background or asterisks 
represent statistically significant differences (adjusted p-value < 0.05) of methylation levels with respect to the control group. NA: Not 
available.
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histological subtypes with respect to non-tumoral tissue 
(Supplementary Table S1). We found that SCC samples 
showed significantly higher hypomethylation levels 
in the SNORD cluster than in lung adenocarcinoma 
(Figure 5A). As with SNORD114-30 for general lung 
cancer, we did not find any statistically significant 
differences for lung adenocarcinoma or SCC (adjusted 
p-value=0.494 and 0.095, respectively). SNORD113-7 
and SNORD114-3 were only statistically significant in 
the SCC group (log2 ratio SCC
+/ non-tumoral tissue = 
-0.309; adjusted p-value= 0.025 and log2 ratio SCC
+/ 
non-tumoral tissue= -0.234; adjusted p-value = 0.031, 
respectively) (Supplementary Table S1). MicroRNA 
clusters were also notably more hypomethylated 
in SCC (Figure 5B). RTL1, MEG8 and LINC00524 
were hypomethylated in both histological subgroups. 
Moreover, DLK1 and MEG9 were significantly 
hypomethylated in patients with SCC (p<0.001 and 
p=0.01, respectively), while in lung adenocarcinoma, 
DLK1 was very similar to the control group (p=0.127). 
DIO3 was significantly hypermethylated in patients 
with lung adenocarcinoma (p<0.001) (Figure 5C).
Transcriptional mapping of the DLK1-DIO3 cluster
To analyze genomic features associated with 
different mechanisms of the transcriptional regulation 
of the DLK1-DIO3 cluster, we used the Wash U 
Epigenome Browser to display the epigenomic mapping 
of the DLK1-DIO3 cluster (14q32) to the human genome 
reference (hg19; chr14: 101.140.120–102.044.779 
genomic coordinates) (Figure 6A). We observed the 
distribution of several transcriptional mechanisms 
(direct regulators and structural determinants) along the 
DLK1-DIO3 cluster (Figure 6B). Multiple enhancers are 
distributed in the length of the cluster (yellow arrows), 
with the exception of the region located between 101380-
10530Kb on chromosome 14. The SNORD113 and 
SNORD114 families and a miRNA cluster are located 
in this region without enhancers. In this same region, 
we found few effects of polycomb protein-mediated 
epigenetic regulation (grey arrows). In addition, we 
identified a heterochromatin rich domain situated 
approximately 101277Kb distal to the 5’ region (purple 
arrows). Therefore, following with MEG9 lncRNA 
(101536Kb), we found a highly condensed region before 
it reached the 5′ region of the DIO3 gene. Interestingly, 
the 5’ flanking region of the MEG3 lncRNA (~101292 
kb) showed activity in transcription initiation, where there 
is an active transcriptional start site (TSS) marked by a 
red arrow. No other region of the DLK1-DIO3 cluster 
showed active TSS. From the active TSS, we found an 
approximately 240Kb a domain with strong transcription 
(green arrows) (Figure 6B). However, we identified 
Figure 2: Validation of the DNA methylation status of the DLK1-DIO3 cluster using TCGA data. The plot shows the methylation 
analysis of the DLK1-DIO3 cluster in lung cancer versus non-tumoral tissue (100 vs. 32 samples) of current and former smokers visualized 
by UCSC browser. Zoomed-in views of the SNORD114-9, miR-889 and DIO3 regions are highlighted in orange squares. A. Chromosome 
14-scale. B. CpG sites included in the Illumina Infinium Human Methylation 450 BeadChip. C. Differential DNA methylation in lung cancer 
versus non-tumoral tissue of current and former smokers. Bars represent hypermethylated (red) and hypomethylated (blue) probes in lung 
cancer tissue with respect to normal tissue. D. ß-value differences between lung cancer and non-tumoral tissue. E. Gene names of the members 
of the DLK1-DIO3 cluster, and F. the position of the CpG islands present in the DLK1-DIO3 cluster (green).
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several CpG islands located near genes throughout this 
region, including lncRNAs, miRNAs, SNORDs and 
pseudogenes (crimson lines) (Figure 6C). However, the 
CpG sites were distributed along the DLK1-DIO3 cluster 
(white lines) (Figure 6D). The GC-content was reduced by 
30% from MEG3 to MEG9 (Figure 6E).
Experimentally validated target interactions of 
the DLK1-DIO3 miRNA cluster
To study the functional relevance of the DLK1-
DIO3 miRNA cluster in the regulation of validated 
mRNAs as a potential tumor suppressor, we used the 
miRWalk algorithm [27]. A total of 538 genes were 
found to be validated targets of the miRNAs included 
in this cluster. These targets were located on all 
chromosomes except the Y chromosome (Figure 7). 
Several miRNAs were complementary with more than 
one validated gene, and some targets were regulated 
by more than one miRNA. We classified validated 
targets by gene ontology (GO) molecular function and 
biological processes using the PANTHER program. 
The main GO molecular functions were binding 
(GO:0005488) (38.9%), catalytic activity (GO:0003824) 
(27.4%), nucleic acid binding transcription factor 
activity (GO:0001071) (13.5%), and receptor activity 
(GO:0004872) (10.4%). The primary binding types 
were protein binding (GO:0005515) and nucleic 
acid binding (GO:0003676). In the case of catalytic 
activity, we primarily found activities for hydrolase 
(GO:0016787), transferase (GO:0016740) and enzyme 
regulators (GO:0007154). Validated targets displayed 
six main biological processes: metabolic processes 
(GO:0008152) (21.2%), such as cell communication 
(GO:0030234) and cell cycle (GO:0007049); cellular 
process (GO:0009987) (20.2%), including system 
development (GO:0048731), anatomical structure 
and morphogenesis (GO:0009653) and death 
(GO:0016265); developmental processes (GO:0032502) 
(12.4%); response to stimulus (GO:0050896) (5.6%); 
and apoptotic processes (GO:0006915) (5.3%) 
(Supplementary Figure S1). Finally, we found that 26 
out of 538 validated genes (AXIN2, BRCA1, CCNB1, 
CCND2, CDKN1A, CDKN2A, CSNK2A1, FOXO1, 
GRB2, HDAC6, NFKB1, NTRK3, PPP2R4, PPP2R1B, 
PPP2R2A, PTEN, RARA, RASA1, RB1, SOCS3, TGFB1, 
TGFB2, TGFBR2, TNF, TP53, and TP73) were targets 
of miRNAs included in the DLK1-DIO3 cluster, which 
have been proposed to have a functional role as tumor 
suppressors (Supplementary Table S2).
Figure 3: mRNA expression levels of some DLK1-DIO3 cluster components. Expression of some DLK1-DIO3 cluster 
components, which was validated by real-time PCR. mRNA expression levels were determined in tumor samples and paired normal lung 




In the present study we firstly identified characteristic 
methylation pattern of the DLK1-DIO3 cluster in 
human lung cancer, as compared, to lung parenchyma. 
Specifically, we identified that all components of the afore-
mentioned cluster are hypomethylated, with the exception 
of DIO3 that is hypermethylated. Importantly this specific 
methylation signature of the imprinted cluster is restricted 
to smoking induced lung cancer since it is absent in lung 
tumors from never smokers. In addition, this locus was 
more aberrantly regulated in SCC, typically exposed to 
heavier smoking history, than in lung adenocarcinoma. In 
a murine lung carcinoma model with mutated KRAS, it has 
been observed that the DLK1-DIO3 miRNAs cluster on 
chromosome on 12qF1 was substantially overexpressed, 
suggesting a role as an oncogenic driver of lung cancer 
in these circumstances [26]. Those findings are consistent 
with our results, particularly considering KRAS is the 
most frequently mutated proto-oncogenes among smokers 
with lung carcinoma [28, 29].
Imprinted genes are particularly more susceptible to 
epigenetic regulatory changes due to having one specifically 
silenced allele [6]. Therefore, monoallelic changes in 
methylation status may have deleterious consequences. 
The DLK1-DIO3 cluster includes protein-coding genes, 
lncRNAs, miRNAs, SNORDs and pseudogenes [21]. 
DLK1, RTL1 and DIO3 are expressed only from the 
paternal allele. However, large and small noncoding RNA 
genes and pseudogenes come from the maternal allele [30]. 
Our data showed that the paternally derived DLK1 and 
RTL1 genes are hypomethylated and that the DIO3 gene 
is hypermethylated. DLK1 has been reported aberrantly 
expressed in various types of tumors, such as hepatocellular 
carcinoma, glioma, renal cell carcinoma and lung cancer 
[31-34]. In addition, Li et al. recently identified in an in 
vitro lung model that overexpression of DLK1 enhanced 
extracellular matrix invasion by Notch signaling in a 
dependent and independent manner [23]. In the case of 
the RTL1 gene, it has been proposed to act as an oncogene 
in hepatocarcinoma. In vivo RTL1 overexpression in the 
liver contributed to tumor growth [24]. Accordingly, the 
hypomethylation of these genes can play an important role 
in the pathogenesis of lung cancer. The hypermethylation 
of DIO3 has been reported in hematologic neoplasms [35]. 
We also identified higher levels of global DNA methylation 
in lung cancer versus normal lung tissue. Moreover, the 
MEG3 lncRNA has been described as a tumor suppressor; 
MEG3 levels were significantly downregulated in patients 
with NSCLC [36]. However, our study showed that the 
Figure 4: Association between smoking behavior and methylation profile of the DLK1-DIO3 cluster. A. DLK1-DIO3 
cluster methylation level differences between non-tumoral and tumoral tissue in non-smoking-related lung cancer patients. (Continued)
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Figure 4: (Continued) Association between smoking behavior and methylation profile of the DLK1-DIO3 cluster. B. 
Validation of the DNA methylation status of DIO3, miR-889 and SNORD114-9 by 454 bisulfite sequencing using pools of 10 non-tumoral 
and tumoral tissue samples in non-smoking-related lung cancer patients. Each column shows the methylation status of an individual CpG and 
the rows (and also the white numbers) indicate the amount of reads. The red arrowheads highlight the position of the CpG represented on the 
Illumina Infinium Human Methylation 450 BeadChip. Methylated CpGs are displayed in purple, unmethylated CpGs in orange and gaps in 
white. C. DLK1-DIO3 cluster methylation level differences between normal tissue and tumoral tissue in smoking-related lung cancer patients, 
including current and former smokers. *: adjusted p-value<0.001. β-value: sum of methylated and unmethylated probe intensities.
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methylation level was significantly higher in human lung 
cancer relative to non-tumoral tissue. These differences 
could be due to the differences between the subjects 
recruited for each study. Lu et al. reported lower MEG3 
expression in patients with an advanced pathological stage 
[36], while in our study, almost 80% of patients were at 
clinical stage I or II. Otherwise, the loss of expression of 
this tumor suppressor could also be due to micro-deletion at 
the MEG3-DMR locus or deletion of a transcription factor-
binding site on the MEG3 promoter [37, 38]. In the case 
of MEG8 and MEG9 lncRNAs, their functions in cancer 
remain unknown.
In our study, we observed an important pattern of 
DNA hypomethylation in two SNORD families and two 
miRNA clusters in patients with lung cancer. In addition, we 
visualized less CpG and strong transcription in this region. 
MicroRNAs are post-transcriptional modulators of many 
biological processes. The dysregulation of their physiological 
roles may contribute to the initiation and progression of 
cancer [39]. Along with miRNAs, other types of small 
regulatory non-protein-coding RNAs were detected, such as 
small nucleolar RNAs (snoRNAs). It has been reported that 
alterations in snoRNA expression levels may lead to various 
diseases, including cancer [40, 41]. Valleron et al. found 
Figure 5: Methylation levels of the DLK1-DIO3 cluster components according to the histological subtype of lung 
cancer. A. Relative SNORD methylation levels in patients with squamous cell carcinoma (SCC) relative to the control group is represented 
in purple bars, whereas methylation levels in patients with adenocarcinoma (ADC) with respect to the control group are represented by 
orange bars. B. Relative microRNA methylation levels in patients with SCC (purple) and ADC (orange) relative to the control group. 
C. Relative methylation levels of DIO3, LINC00524, MEG9, MEG8, RTL1, MEG3 and DLK1 in patients with SCC (purple) and ADC 
(orange) with respect to the control group. Black broken lines represent statistically significant differences (adjusted p-value < 0.05) of 
methylation levels with respect to the control group.
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that several variants of SNORDs of the DLK1-DIO3 cluster 
were overexpressed in patients with acute promyelocytic 
leukemia (APL) [42]. In addition, it has been shown that 
in vitro SNORD114-1 overexpression promoted cell growth 
by cell cycle modulation [42]. The same results have been 
obtained in a large cohort of of acute promyelocytic leukemia 
(APL) patients, suggesting that increased expression of 
SNORD114-3 is a good biomarker of APL [43]. In our study, 
we identified that the increased expression of SNORD114-3 
was only statistically significant in the SCC group although 
a tendency was observed in the lung adenocarcinoma group. 
The DLK1-DIO3 cluster contains also 53 miRNAs. The 
deregulation of some of them has been associated with 
enhanced tumorigenicity [22]. MicroRNA-154, miR-379 
and miR-409 were highly expressed in metastatic prostate 
cancer cells [44]. MicroRNA-127 was overexpressed in the 
serum of patients with esophageal squamous cell carcinoma 
[45]. Haller et al. revealed the deregulation of miRNA-329, 
miR-370, miR-376c and miR409 expression based on the 
location of the tumor in gastrointestinal stromal tumors 
(GISTs); higher expression occurred in intestinal compared 
to gastric tumors [46]. Indeed, it has even been proposed that 
miR-376c can promote cell proliferation and invasion [47, 
48]. Recently, miRNAs of the DLK1-DIO3 cluster have been 
identified as being upregulated in a mouse model of lung 
adenocarcinoma [26]. The results obtained in a mouse model 
are in line with those obtained from the patient cohort of our 
study. We found a pattern of DNA hypomethylation in the 
DLK1-DIO3 microRNA cluster in current and former smoker 
patients with lung cancer. This profile was representative of 
both SCC and lung adenocarcinoma histological subtypes. 
On the other hand, it has been found that hepatocellular 
carcinoma patients with overexpression of the DLK1-DIO3 
miRNA cluster had significantly poorer overall survival 
[49]. In addition, 3 miRNAs of the DLK1-DIO3 cluster have 
been associated with poor survival in patients with surgically 
resected lung adenocarcinoma [50]. These data warrant 
a validation of the DLK1-DIO3 cluster methylation as a 
prognostic tool in a prospective cohort study.
We identified experimentally validated targets and 
predicted their molecular function. We found that they may 
be involved in catalytic activity and the binding of nucleic 
acids to transcription factors. The biological process 
categories were mostly metabolic, cellular, developmental, 
response to stimulus and apoptotic processes. In 
addition, we identified 26 validated targets, including 
AXIN2, BRCA1, CCNB1, CCND2, CDKN1A, CDKN2A, 
CSNK2A1, FOXO1, GRB2, HDAC6, NFKB1, NTRK3, 
Figure 6: Transcriptional mapping of the DLK1-DIO3 cluster to the human reference genome hg19. A. Chromosome 
14 ideogram. The DLK1-DIO3 cluster is located on 14q32. The exact position of the cluster in the region is marked with a blue square. 
B. Chromosome position. Base pairs of the DLK1-DIO3 cluster on chromosome 14 (highlighted in yellow). The transcriptional mechanisms 
underlying the expression of the DLK1-DIO3 cluster, such as the transcription start sites (TSS), enhancer regions (Enh), zinc finger (ZNF), 
packed form of DNA, and polycomb group proteins. C. CpG islands in the DLK1-DIO3 cluster (crimson lines). D. The genomic distribution 
of CpG sites in the DLK1-DIO3 cluster (white lines). E. GC percent in the DLK1-DIO3 cluster (blue). Finally, the sequence references of 
members of the DLK1-DIO3 cluster are represented.
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PPP2R4, PPP2R1B, PPP2R2A, PTEN, RARA, RASA1, 
RB1, SOCS3, TGFB1, TGFB2, TGFBR2, TNF, TP53, 
and TP73, which can act as tumor suppressors. Thus, the 
hypomethylation of the DLK1-DIO3 miRNA cluster may 
lead to its activation, promoting the downregulation of 
these relevant tumor suppressors in lung cancer.
In conclusion, we found the DLK1-DIO3 cluster 
to be hypomethylated in current and former smoker 
patients with NSCLC. This pattern suggests that aberrant 
expression may contribute to tumorigenesis in the lung. 
Moreover, given that some components of the DLK1-
DIO3 cluster may be responsible of the regulation of 
tumor suppressors in lung cancer, they could have great 
potential as novel biomarkers and therapeutic targets. The 
present analysis suggests that future studies on this topic 
are warranted.
Figure 7: Validated targets of miRNAs contained in the DLK1-DIO3 cluster. Plot showing with position of validated miRNA 




Patients and clinical specimens
The present study was performed in 70 subjects 
fromVirgen del Rocio University Hospital (Seville). The 
samples were divided into two cohorts. A first group of 
samples, from 47 patients who had undergone surgical 
resection for clinical early stage NSCLC. During the 
surgical procedure, the tumor and matched non-tumoral 
tissue samples were collected from all patients and then 
immediately snap-frozen to −80°C until further use. The 
clinical features of patients with NSCLC are summarized 
in Supplementary Table S3. A second group from 23 
subjects was used as control cohort. The control cohort 
without lung cancer was constituted of COPD patients and 
non-COPD subjects. A description of this cohort can be 
found on Supplementary Table S4. A written consent form 
was obtained from all participants. The study protocol and 
the use of human samples were approved by the Ethical 
Committee of the Virgen del Rocio University Hospital.
DNA samples
Genomic DNA was extracted from tumor and matched 
non-tumoral tissue samples by the QIAamp DNA mini kit 
(QIAGEN, Valencia, CA, USA). DNA was quantified using 
the QuantiFluor dsDNA system (Promega, Madison, WI, 
USA) according to the manufacturers’ instructions.
Illumina 450 K methylation
The Illumina Infinium Human Methylation 450 
BeadChip (Illumina Inc., San Diego, CA) was used to 
interrogate 485,000 methylation sites across the genome 
per sample at single-nucleotide resolution. It covers 96% 
of the CpG islands, with additional coverage in island 
shores and the flanking regions. We treated 500 ng of DNA 
with sodium bisulfate using the EZ DNA Methylation™ 
Kit and cleaned the DNA with the ZR-96 DNA Clean-
up Kit™ (EZ DNA, Zymo Research, Irvine, CA) before 
standard Illumina amplification, hybridization, and 
imaging steps. The resulting intensity files were analyzed 
with Illumina’s GenomeStudio, which generated β-scores 
(i.e., the proportion of total signal from the methylation-
specific probe or color channel).
Methylome data processing
Methylome data were processed using the RnBeads 
R package [51]. After a quality check, the probe median 
intensity was normalized with the SWAN method [52] 
and converted to beta values. The probes were tested for 
differential methylation with the limma method, a linear 
model followed by empirical Bayes methods for the 
comparisons of interest [53]. The Benjamini–Hochberg 
method was used to adjust the p-values and ensure that 
the false discovery rate (FDR) was lower than 0.05. The 
CpG status (hypo- versus hyper-methylated) and CpG 
chromosomal location were realized using the Circos 
data visualization software [54]. DNA methylation data 
were visualized by the Wash U Epigenome Browser [55]. 
Validated mRNA targets of miRNAs by previous research 
located in the DLK1-DIO3 cluster were identified with 
the miRWalk algorithm [27]. The molecular function 
and proposed biological process of experimentally 
verified mRNAs were determined using the PANTHER 
program [56].
Validation of DNA methylation status
Smoking-related samples from lung cancer patients 
in TCGA database (https://tcga-data.nci.nih.gov) were 
selected to interrogate the DLK1-DIO3 cluster methylation 
status. Their characteristics are summarized in Table S5. 
Differences on the DLK1-DIO3 methylation profile 
between tumor and normal tissues from current and former 
smoker lung cancer patients were identified with a method 
previously described [57]. Non-smoking habit of lung 
cancer patients in TCGA database were often incomplete. 
For this reason, 454 bisulfite sequencing (Roche, 
Mannheim, Germany) was used to validate the DNA 
methylation status of DLK1, miR-889 and SNORD114-9 
[58]. Primer sequences are listed in Supplementary table 
S6 and the genomic features of regions selected for 454 
bisulfite sequencing are represented in Supplementary 
Figure S2.
Expression levels of some DLK1-DIO3 cluster 
components
Expression of some randomly selected DLK1-DIO3 
cluster components (DIO3, SNORD113-5, SNORD113-7, 
SNORD114-9, and miR-889) was analyzed by qPCR. For 
genes, 100 ng/µL of total RNA was converted into cDNA 
by the reverse transcriptase reaction which was performed 
by sequential incubation at 25°C for 10 min, 37°C for 
2 h and 85°C for 5 min. For the miR-889 expression 
levels, 2 ng/µL of total RNA was converted into cDNA by 
the reverse transcriptase reaction, which was performed 
by sequential incubation at 16°C for 30 min, 42°C for 
30 min and 85°C for 5 min. The PCR reaction mixture 
was initially incubated at 95°C for 10 min, followed 
by 40 cycles of 95°C for 15 seconds and 60°C for 60 
seconds. The expression of miR-889 was normalized to 
the expression of RNU48 and B2M for the normalization 
of different genes. Gene expression data of tumor versus 
normal tissue were compared by a t-test. The results were 
processed and analyzed as previously described [59, 60].
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